A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period

An International Study to Characterize the Disease Behaviour of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease During the Peri-Diagnostic Period

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03261037

Enrollment

178

Registered

2017-08-24

Start date

2017-12-25

Completion date

2019-11-27

Last updated

2021-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease

Brief summary

This international clinical study will enroll participants with a suspected diagnosis of IPF/ILD. This study will characterize the disease behavior of IPF and ILD in the peri-diagnostic period. This objective will be achieved using a multidimensional approach assessing changes in pulmonary function, measured by daily handheld spirometry and site spirometry as well as assessing physical functional capacity at home (accelerometry) and at site (6-minute walk tests \[6MWT\]). Daily handheld spirometry or physical functional capacity assessments are not routinely performed in this participant population. By following participants' lung function before and after diagnosis using home spirometry, levels of physical activity, as well as self-assessment data from the participants (patient reported outcomes; PRO), the study would provide potentially more rapid information on disease behavior and eventually progression compared to usual clinic measurements that occur only every 3-6 months. By receiving data from daily handheld spirometry measurements, treating physicians may have an improved chance of detecting earlier and outside of hospital visits a decline in lung function that could potentially lead to improvements in both diagnosis and treatment for participants with IPF/ILD.

Interventions

OTHERSpirometry

Daily spirometry will be conducted by the participant at home using the study kit provided. Spirometry assessments (FVC) will be conducted at approximately the same time each day with the participant in a seated position. Additionally, site spirometry will also be performed during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.

OTHERAccelerometry

Daily physical functional capacity assessments (e.g., steps per day, calorie expenditure) will be measured on an ongoing basis using the accelerometry device provided.

OTHER6MWT

The 6MWT will be performed only at sites where a formalized process is available and the test can be performed under safe conditions, during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Able to comply with the study protocol, in the Investigator's judgment - for example, the ability to use the provided spirometer and tablet and the ability to fill in the required patient reported outcomes questionnaires * Suspicion of IPF/ILD: radiological evidence of IPF/ILD in symptomatic participants (unexplained dyspnea on exertion and/or cough)

Exclusion criteria

* Participation in any investigational study within 28 days prior to inclusion * History of clinically significant cardiac disease that could explain the patient's symptomatology in the opinion of the Investigator * Known history of any connective tissue disease, including, but not limited to, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, or mixed connective tissue disease

Design outcomes

Primary

Measure	Time frame	Description
Time-Adjusted Semi-Annual Forced Vital Capacity (FVC) Decline in Participants With IPF During the Peri-Diagnostic Period, Measured in Milliliters (mL) by Daily Home Spirometry	From Day 1 into the study to end of the study (up to 18 months) and adjusted for 6 months. There was no fixed visit schedule for the whole study and reported results comprise all data points from enrollment to EOS	Minimum site visits were: baseline, diagnosis, and EOS for each participant. From inclusion into the study, participants were followed for up to12 months. The EOS was defined as: If no diagnosis was made 12 months after inclusion, the participant left the study; Participants diagnosed with non-ILD left the study on the date of diagnosis; Participants diagnosed with IPF or non-IPF ILD were followed up to the start of drug treatment (within 6 months) or up to 6 months if no drug treatment was prescribed. Therefore, the total length of the study was variable for each participant. Measurements were taken daily by home spirometry. The semi-annual mean FVC decline was calculated by use of the estimated semi-annual FVC decline of each individual participant. The individual FVC decline was estimated by applying a linear regression model to all acceptable FVC measurements flagged as 'Good blow' collected by the individual participant during the entire peri-diagnostic period (up to 18 months).

Secondary

Measure	Time frame	Description
Change From Baseline in the FVC Decline in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured in mL by Site Spirometry	From Baseline to end of the study (up to 18 months)	The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Change From Baseline in the Percent Predicted FVC in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Site Spirometry	From Baseline to end of the study (up to 18 months)	The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Change From Baseline in Distance Walked (Meters) on the 6MWT in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Assessed at Site	From Baseline to end of the study (up to 18 months)	The 6MWT measures the distance a patient is able to walk quickly on a flat, hard surface in a period of 6 minutes. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Decline in Physical Function Capacity (Steps/Day) in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry	From inclusion into the study to end of the study (up to 18 months)	Patients were asked to wear an accelerometer during the course of the study which provided information on their physical activity at home, with daily measurements used to investigate the development of physical function capacity. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Calorie Expenditure in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry	From inclusion into the study to end of the study (up to 18 months)	—
Change in the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score by Visit During the Peri-Diagnostic Period	From inclusion into the study to end of the study (up to 18 months)	The K-BILD questionnaire was specifically developed to analyze the health status of participants with ILD. The questionnaire consists of 15 items (assessed by the patients on a scale ranging from 1 to 7, where 1 and 7 represent worst and best health status). Items are compiled into 3 domains: breathlessness and activities (range: 0-21), psychological (range: 0-34) , and chest symptoms (range: 0-8). To score the K-BILD, the Likert response scale weightings for individual items are combined and scores are transformed to a range of 0-100 by using logit values (higher scores indicate better health status). The peri-diagnostic period covered the pre-diagnostic period (from enrollment visit participants were followed for up to 12 months) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	From inclusion into the study to end of the study (up to 18 months)	The mMRC dyspnea scale was used to grade the effects of breathlessness on daily activities over time. The following grading categories are used for this scale: Grade 0 - I only get breathless with strenuous exercise; Grade 1 - I get short of breath when hurrying on the level or walking up a slight hill; Grade 2 - I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking on my own pace; Grade 3 - I stop for breath after walking about 100 yards or after a few minutes on level ground; Grade 4 - I am too breathless to leave the house. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	From inclusion into the study to end of the study (up to 18 months)	The EQ-5D-5L questionnaire is a self-reported health status questionnaire that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each item is rated by the participant on a five-point scale indicating the followings: Level 1 - no problem; Level 2 - slight problems; Level 3 - moderate problems; Level 4 - severe problems; Level 5 - extreme problems. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Percentage of Participants With Non-Elective Hospitalizations	From inclusion into the study to end of the study (up to 18 months)	The number of participants requiring the hospitalization were counted during pre- and post-diagnosis period. Investigator-reported acute exacerbations, deaths, and events related to study assessments were only collected in the clinical database. As the study had no protocol mandated IMP or treatment requirements, any untoward occurrences such as AEs and SAEs were not collected.
The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period	From inclusion into the study to end of the study (up to 18 months)	The EQ-VAS questionnaire is a self-reported questionnaire that measures health state. The VAS is a 100 mm scale from worst (0 mm) to best (100 mm) health the participant can imagine. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Time-Adjusted Semi-Annual FVC Decline in Participants With Non-IPF ILD During the Peri-Diagnostic Period, Measured in mL by Daily Home Spirometry	From Day 1 into the study to end of the study (up to 18 months) and adjusted for 6 months. There was no fixed visit schedule for the whole study and reported results comprise all data points from enrollment to EOS	Minimum site visits were: baseline, diagnosis, and EOS for each participant. From inclusion into the study, participants were followed for up to12 months. The EOS was defined as: If no diagnosis was made 12 months after inclusion, the participant left the study; Participants diagnosed with non-ILD left the study on the date of diagnosis; Participants diagnosed with IPF or non-IPF ILD were followed up to the start of drug treatment (within 6 months) or up to 6 months if no drug treatment was prescribed. Therefore, the total length of the study was variable for each participant. Measurements were taken daily by home spirometry. The semi-annual mean FVC decline was calculated by use of the estimated semi-annual FVC decline of each individual participant. The individual FVC decline was estimated by applying a linear regression model to all acceptable FVC measurements flagged as 'Good blow' collected by the individual participant during the entire peri-diagnostic period (up to 18 months).
Fatigue Assessment Scale (FAS) Score During the Peri-Diagnostic Period	From inclusion into the study to end of the study (up to 18 months)	The FAS is a fatigue questionnaire consisting of 10 items; five questions reflect physical fatigue and five questions analyze mental fatigue. A five-point scale (one for never to five for always) is used for participant responses. The scale score is calculated by summing all items. Therefore, the FAS scores can range from 10 to 50. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	From inclusion into the study to end of the study (up to 18 months)	The VAS are 100 mm scales on which participants indicate the severity of their cough, the urge to cough and their fatigue. In the VAS, participants had to record their health state on a scale ranging from 0 (best imaginable health state) to 100 (worst imaginable health state). A mean of this health state was recorded for participant analyzed in this outcome measure. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Pearson's Correlation Coefficient of FVC (mL) Between Home and Site Spirometry in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period	From inclusion into the study to end of the study (up to 18 months)	The correlation of FVC (mL) between home and site spirometry was analyzed by taking into account the individually estimated linear regression models of each participant for home-based FVC measurements and site FVC measurements. This analysis was performed for participants diagnosed with IPF or non-IPF ILD in the peri-diagnosis period. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Pearson's Correlation Coefficient of Physical Functional Capacity Assessed at Home in Terms of the Decline in the Number of Footsteps and on Site in Terms of the Decline in Distance of the 6MWT	From inclusion into the study to end of the study (up to 18 months)	The measure represents the correlation of distance walked (meter) assessed by physical function capacity at home and the 6MWT at the site in the peri-diagnosis period. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Percentage of Participants Requiring Respiratory-Related Hospitalizations	From inclusion into the study to end of the study (up to 18 months)	The number of participants requiring the hospitalization were counted during pre- and post-diagnosis period.
Percentage of Participants With Investigator-Reported Acute Exacerbations	From inclusion into the study to end of the study (up to 18 months)	Acute exacerbation was defined as per Collard et al. 2016. Investigator-reported acute exacerbations, deaths, and events related to study assessments were only collected in the clinical database. As the study had no protocol mandated IMP or treatment requirements, any untoward occurrences such as AEs and SAEs were not collected.
Percentage of Participants Who Died Due to Any Cause	From inclusion into the study to end of the study (up to 18 months)	The number of participants, who died due to any cause, were counted during pre- and post-diagnosis period.
Percentage of Participants Who Died Due to Respiratory-Related Diseases	From inclusion into the study to end of the study (up to 18 months)	The number of participants, who died due to respiratory-related diseases, were counted during pre- and post-diagnosis period.
Percentage of Participants With Events Related to the Study Assessments	From inclusion into the study to end of the study (up to 18 months)	The number of participants with events related to the study assessments were counted during pre- and post-diagnosis period. Investigator-reported acute exacerbations, deaths, and events related to study assessments were only collected in the clinical database. As the study had no protocol mandated IMP or treatment requirements, any untoward occurrences such as AEs and SAEs were not collected.
The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period	From inclusion into the study to end of the study (up to 18 months)	The EQ-5D-5L questionnaire is a self-reported health status questionnaire that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. A unique health state is defined for each participant by combining the levels from each of the 5 dimensions. Each state is referred to in terms of a 5 digit code, e.g. state 11111 indicates no problems on any of the 5 dimensions, while state 12345 indicates no problems with mobility, slight problems with washing or dressing, moderate problems with usual activities, severe pain or discomfort and extreme anxiety or depression. From these 5 answers an index value is derived between 0 and 1, with a higher value corresponding with a better Quality of Life.

Countries

Canada, France, Ireland, Italy, Netherlands, Russia

Participant flow

Recruitment details

The study enrolled participants in Canada, France, Ireland, Italy, the Netherlands, and Russia.

Participants by arm

Arm	Count
IPF Participants Participants diagnosed with Idiopathic Pulmonary Fibrosis (IPF)	68
Non-IPF ILD Participants Participants diagnosed with an Interstitial Lung Disease (ILD) other than Idiopathic Pulmonary Fibrosis (non-IPF)	62
Non-ILD Participants Participants diagnosed with a condition that was not an Interstitial Lung Disease (non-ILD)	9
Participants Without Diagnosis Participants without diagnosis	39
Total	178

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG003
Overall Study	Diagnosed but protocol deviation	1	0	0
Overall Study	End of study for participant and no follow up	0	0	1
Overall Study	Equipment failed to work	0	0	1
Overall Study	Non-compliance with study procedures	0	2	6
Overall Study	Participant came out of study due to investigator discretion	0	2	0
Overall Study	Participant did not want to continue the diagnostic procedures	0	0	1
Overall Study	Participant did not want to continue the study	0	1	0
Overall Study	Participant moving away and can no longer be in study	0	1	0
Overall Study	Participant presented clinical improvement	0	2	0
Overall Study	Participant was too weak to continue in study	1	0	0
Overall Study	Technical difficulties	0	0	1
Overall Study	Withdrawal by Subject	2	13	18

Baseline characteristics

Characteristic	IPF Participants	Non-ILD Participants	Participants Without Diagnosis	Total	Non-IPF ILD Participants
Age, Continuous	69.3 Years STANDARD_DEVIATION 6.97	69.6 Years STANDARD_DEVIATION 7.7	71.2 Years STANDARD_DEVIATION 8.64	68.3 Years STANDARD_DEVIATION 8.8	65.1 Years STANDARD_DEVIATION 9.99
Race/Ethnicity, Customized American Indian or Alaskan Native	1 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Race/Ethnicity, Customized Hispanic or Latino	9 Participant	0 Participant	1 Participant	22 Participant	12 Participant
Race/Ethnicity, Customized Missing	5 Participants	2 Participants	15 Participants	33 Participants	11 Participant
Race/Ethnicity, Customized Not Hispanic or Latin	49 Participant	7 Participant	20 Participant	112 Participant	36 Participant
Race/Ethnicity, Customized Not reported	4 Participant	0 Participant	2 Participant	9 Participant	3 Participant
Race/Ethnicity, Customized Unknown	1 Participant	0 Participants	0 Participants	1 Participants	1 Participants
Race/Ethnicity, Customized White	62 Participants	7 Participants	24 Participants	143 Participants	50 Participants
Sex: Female, Male Female	19 Participants	3 Participants	12 Participants	66 Participants	32 Participants
Sex: Female, Male Male	49 Participants	6 Participants	27 Participants	112 Participants	30 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	0 / 68	0 / 62	0 / 9	0 / 39
other Total, other adverse events	0 / 0	0 / 0	0 / 0	0 / 0
serious Total, serious adverse events	0 / 0	0 / 0	0 / 0	0 / 0

Outcome results

Primary

Time-Adjusted Semi-Annual Forced Vital Capacity (FVC) Decline in Participants With IPF During the Peri-Diagnostic Period, Measured in Milliliters (mL) by Daily Home Spirometry

Minimum site visits were: baseline, diagnosis, and EOS for each participant. From inclusion into the study, participants were followed for up to12 months. The EOS was defined as: If no diagnosis was made 12 months after inclusion, the participant left the study; Participants diagnosed with non-ILD left the study on the date of diagnosis; Participants diagnosed with IPF or non-IPF ILD were followed up to the start of drug treatment (within 6 months) or up to 6 months if no drug treatment was prescribed. Therefore, the total length of the study was variable for each participant. Measurements were taken daily by home spirometry. The semi-annual mean FVC decline was calculated by use of the estimated semi-annual FVC decline of each individual participant. The individual FVC decline was estimated by applying a linear regression model to all acceptable FVC measurements flagged as 'Good blow' collected by the individual participant during the entire peri-diagnostic period (up to 18 months).

Time frame: From Day 1 into the study to end of the study (up to 18 months) and adjusted for 6 months. There was no fixed visit schedule for the whole study and reported results comprise all data points from enrollment to EOS

Population: Participants diagnosed with IPF. Only participants for whom data were collected are included in the analysis.

Arm	Measure	Value (MEAN)	Dispersion
IPF Participants	Time-Adjusted Semi-Annual Forced Vital Capacity (FVC) Decline in Participants With IPF During the Peri-Diagnostic Period, Measured in Milliliters (mL) by Daily Home Spirometry	-308.7 milliliter (mL)	Standard Deviation 1268.72

Secondary

Calorie Expenditure in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry

Time frame: From inclusion into the study to end of the study (up to 18 months)

Population: Data collection was impacted by technical problems that could not be solved, thus invalid data collected was not analyzed.

Arm	Measure	Value (NUMBER)
IPF Participants	Calorie Expenditure in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry	NA Calorie
Non-IPF ILD Participants	Calorie Expenditure in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry	NA Calorie

Secondary

Change From Baseline in Distance Walked (Meters) on the 6MWT in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Assessed at Site

The 6MWT measures the distance a patient is able to walk quickly on a flat, hard surface in a period of 6 minutes. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame: From Baseline to end of the study (up to 18 months)

Population: Participants diagnosed with IPF and non-IPF ILD. Only participants for whom data were collected are included in the analysis.

Arm	Measure	Group	Value (MEAN)	Dispersion
IPF Participants	Change From Baseline in Distance Walked (Meters) on the 6MWT in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Assessed at Site	Baseline	434.6 Meter (m)	Standard Deviation 117.3
IPF Participants	Change From Baseline in Distance Walked (Meters) on the 6MWT in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Assessed at Site	Change from Baseline at End of Study Visit	4.4 Meter (m)	Standard Deviation 96.18
Non-IPF ILD Participants	Change From Baseline in Distance Walked (Meters) on the 6MWT in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Assessed at Site	Baseline	429.4 Meter (m)	Standard Deviation 139.51
Non-IPF ILD Participants	Change From Baseline in Distance Walked (Meters) on the 6MWT in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Assessed at Site	Change from Baseline at End of Study Visit	6.4 Meter (m)	Standard Deviation 87.97

Secondary

Change From Baseline in the FVC Decline in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured in mL by Site Spirometry

The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame: From Baseline to end of the study (up to 18 months)

Population: Participants diagnosed with IPF and non-IPF ILD. Only participants for whom data were collected are included in the analysis.

Arm	Measure	Group	Value (MEAN)	Dispersion
IPF Participants	Change From Baseline in the FVC Decline in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured in mL by Site Spirometry	Baseline	2845.6 mL	Standard Deviation 814.83
IPF Participants	Change From Baseline in the FVC Decline in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured in mL by Site Spirometry	Change from Baseline at End of Study Visit	-51.3 mL	Standard Deviation 270.56
Non-IPF ILD Participants	Change From Baseline in the FVC Decline in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured in mL by Site Spirometry	Baseline	2782.4 mL	Standard Deviation 870.24
Non-IPF ILD Participants	Change From Baseline in the FVC Decline in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured in mL by Site Spirometry	Change from Baseline at End of Study Visit	-27.1 mL	Standard Deviation 265.52

Secondary

Change From Baseline in the Percent Predicted FVC in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Site Spirometry

Time frame: From Baseline to end of the study (up to 18 months)

Population: Participants diagnosed with IPF and non-IPF ILD. Only participants for whom data were collected are included in the analysis.

Arm	Measure	Group	Value (MEAN)	Dispersion
IPF Participants	Change From Baseline in the Percent Predicted FVC in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Site Spirometry	Baseline	82.8 Percent Predicted (%)	Standard Deviation 18.74
IPF Participants	Change From Baseline in the Percent Predicted FVC in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Site Spirometry	Change form Baseline at End of Study Visit	-0.6 Percent Predicted (%)	Standard Deviation 7.26
Non-IPF ILD Participants	Change From Baseline in the Percent Predicted FVC in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Site Spirometry	Baseline	83.9 Percent Predicted (%)	Standard Deviation 17.82
Non-IPF ILD Participants	Change From Baseline in the Percent Predicted FVC in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Site Spirometry	Change form Baseline at End of Study Visit	-0.6 Percent Predicted (%)	Standard Deviation 8.49

Secondary

Change in the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score by Visit During the Peri-Diagnostic Period

The K-BILD questionnaire was specifically developed to analyze the health status of participants with ILD. The questionnaire consists of 15 items (assessed by the patients on a scale ranging from 1 to 7, where 1 and 7 represent worst and best health status). Items are compiled into 3 domains: breathlessness and activities (range: 0-21), psychological (range: 0-34) , and chest symptoms (range: 0-8). To score the K-BILD, the Likert response scale weightings for individual items are combined and scores are transformed to a range of 0-100 by using logit values (higher scores indicate better health status). The peri-diagnostic period covered the pre-diagnostic period (from enrollment visit participants were followed for up to 12 months) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame: From inclusion into the study to end of the study (up to 18 months)

Population: All enrolled participants completed the questionnaire. Only participants for whom data were collected are included in the analysis.

Arm	Measure	Group	Value (MEAN)	Dispersion
IPF Participants	Change in the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score by Visit During the Peri-Diagnostic Period	Baseline	60.57 Units on scale	Standard Deviation 17.633
IPF Participants	Change in the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score by Visit During the Peri-Diagnostic Period	Change from Baseline at End of Study Visit	-0.45 Units on scale	Standard Deviation 9.709
Non-IPF ILD Participants	Change in the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score by Visit During the Peri-Diagnostic Period	Change from Baseline at End of Study Visit	3.98 Units on scale	Standard Deviation 11.851
Non-IPF ILD Participants	Change in the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score by Visit During the Peri-Diagnostic Period	Baseline	55.70 Units on scale	Standard Deviation 14.203
Non-ILD Participants	Change in the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score by Visit During the Peri-Diagnostic Period	Baseline	54.22 Units on scale	Standard Deviation 11.703
Non-ILD Participants	Change in the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score by Visit During the Peri-Diagnostic Period	Change from Baseline at End of Study Visit	6.03 Units on scale	Standard Deviation 14.294
Participants Without Diagnosis	Change in the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score by Visit During the Peri-Diagnostic Period	Baseline	60.47 Units on scale	Standard Deviation 15.728
Participants Without Diagnosis	Change in the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score by Visit During the Peri-Diagnostic Period	Change from Baseline at End of Study Visit	4.01 Units on scale	Standard Deviation 9.313

Secondary

Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period

The VAS are 100 mm scales on which participants indicate the severity of their cough, the urge to cough and their fatigue. In the VAS, participants had to record their health state on a scale ranging from 0 (best imaginable health state) to 100 (worst imaginable health state). A mean of this health state was recorded for participant analyzed in this outcome measure. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame: From inclusion into the study to end of the study (up to 18 months)

Population: All enrolled participants. Only participants for whom data were collected are included in the analysis. Data of post-diagnosis period for non-ILD participants and participants without diagnosis were not collected.

Arm	Measure	Group	Value (MEAN)	Dispersion
IPF Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	End of Study (Fatigue)	38.3 Scores on a Scale	Standard Deviation 26.15
IPF Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	End of Study (Urge to Cough)	33.8 Scores on a Scale	Standard Deviation 25.18
IPF Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Post-diagnosis (Urge to Cough)	23.5 Scores on a Scale	Standard Deviation 15.79
IPF Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Baseline (Urge to Cough)	33.3 Scores on a Scale	Standard Deviation 25.41
IPF Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Initial diagnosis (Fatigue)	37.5 Scores on a Scale	Standard Deviation 27.5
IPF Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Initial diagnosis (Urge to Cough)	36.4 Scores on a Scale	Standard Deviation 29.22
IPF Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Pre-diagnosis (Urge to Cough)	37.6 Scores on a Scale	Standard Deviation 25.73
IPF Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Pre-diagnosis (Fatigue)	34.1 Scores on a Scale	Standard Deviation 27.5
IPF Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Initial diagnosis (Cough)	36.3 Scores on a Scale	Standard Deviation 29.6
IPF Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Post-diagnosis (Fatigue)	30.4 Scores on a Scale	Standard Deviation 23.24
IPF Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Baseline (Fatigue)	38.4 Scores on a Scale	Standard Deviation 27.15
IPF Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Baseline (Cough)	34.0 Scores on a Scale	Standard Deviation 25.44
IPF Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Post-diagnosis (Cough)	25.6 Scores on a Scale	Standard Deviation 20.94
IPF Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Pre-diagnosis (Cough)	36.8 Scores on a Scale	Standard Deviation 25.5
IPF Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	End of Study (Cough)	34.7 Scores on a Scale	Standard Deviation 26.64
Non-IPF ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	End of Study (Urge to Cough)	24.3 Scores on a Scale	Standard Deviation 20.14
Non-IPF ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Baseline (Cough)	26.9 Scores on a Scale	Standard Deviation 20.66
Non-IPF ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Pre-diagnosis (Cough)	25.4 Scores on a Scale	Standard Deviation 20.9
Non-IPF ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Initial diagnosis (Cough)	21.9 Scores on a Scale	Standard Deviation 18.88
Non-IPF ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Post-diagnosis (Cough)	17.0 Scores on a Scale	Standard Deviation 9.16
Non-IPF ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	End of Study (Cough)	24.0 Scores on a Scale	Standard Deviation 19.42
Non-IPF ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Baseline (Urge to Cough)	28.6 Scores on a Scale	Standard Deviation 21.53
Non-IPF ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Pre-diagnosis (Urge to Cough)	23.1 Scores on a Scale	Standard Deviation 20.03
Non-IPF ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Initial diagnosis (Urge to Cough)	22.9 Scores on a Scale	Standard Deviation 19.02
Non-IPF ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Post-diagnosis (Urge to Cough)	10.8 Scores on a Scale	Standard Deviation 9
Non-IPF ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Baseline (Fatigue)	39.4 Scores on a Scale	Standard Deviation 24.29
Non-IPF ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Pre-diagnosis (Fatigue)	31.0 Scores on a Scale	Standard Deviation 22.68
Non-IPF ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Initial diagnosis (Fatigue)	35.6 Scores on a Scale	Standard Deviation 23.79
Non-IPF ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Post-diagnosis (Fatigue)	25.3 Scores on a Scale	Standard Deviation 19.48
Non-IPF ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	End of Study (Fatigue)	34.6 Scores on a Scale	Standard Deviation 23.54
Non-ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Initial diagnosis (Cough)	17.1 Scores on a Scale	Standard Deviation 21.69
Non-ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Pre-diagnosis (Fatigue)	32.5 Scores on a Scale	Standard Deviation 26.11
Non-ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	End of Study (Fatigue)	35.5 Scores on a Scale	Standard Deviation 32.16
Non-ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Pre-diagnosis (Cough)	11.4 Scores on a Scale	Standard Deviation 14.03
Non-ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Baseline (Fatigue)	30.0 Scores on a Scale	Standard Deviation 31.18
Non-ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Initial diagnosis (Fatigue)	31.1 Scores on a Scale	Standard Deviation 30
Non-ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Pre-diagnosis (Urge to Cough)	13.2 Scores on a Scale	Standard Deviation 13.51
Non-ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	End of Study (Urge to Cough)	16.2 Scores on a Scale	Standard Deviation 20
Non-ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Baseline (Urge to Cough)	16.4 Scores on a Scale	Standard Deviation 17.2
Non-ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	End of Study (Cough)	19.3 Scores on a Scale	Standard Deviation 21.35
Non-ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Initial diagnosis (Urge to Cough)	13.7 Scores on a Scale	Standard Deviation 19.86
Non-ILD Participants	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Baseline (Cough)	17.9 Scores on a Scale	Standard Deviation 21.99
Participants Without Diagnosis	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Initial diagnosis (Urge to Cough)	38.5 Scores on a Scale	Standard Deviation 47.38
Participants Without Diagnosis	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Baseline (Cough)	27.4 Scores on a Scale	Standard Deviation 20.38
Participants Without Diagnosis	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Initial diagnosis (Cough)	32.0 Scores on a Scale	Standard Deviation 36.77
Participants Without Diagnosis	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	End of Study (Urge to Cough)	36.3 Scores on a Scale	Standard Deviation 29.75
Participants Without Diagnosis	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Baseline (Fatigue)	33.2 Scores on a Scale	Standard Deviation 26.89
Participants Without Diagnosis	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Pre-diagnosis (Cough)	31.4 Scores on a Scale	Standard Deviation 24.34
Participants Without Diagnosis	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	End of Study (Fatigue)	31.5 Scores on a Scale	Standard Deviation 24.18
Participants Without Diagnosis	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Pre-diagnosis (Fatigue)	32.0 Scores on a Scale	Standard Deviation 28.29
Participants Without Diagnosis	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Baseline (Urge to Cough)	25.8 Scores on a Scale	Standard Deviation 21.27
Participants Without Diagnosis	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Pre-diagnosis (Urge to Cough)	30.4 Scores on a Scale	Standard Deviation 24.29
Participants Without Diagnosis	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	Initial diagnosis (Fatigue)	17.0 Scores on a Scale	Standard Deviation 5.66
Participants Without Diagnosis	Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period	End of Study (Cough)	31.2 Scores on a Scale	Standard Deviation 25.92

Secondary

Decline in Physical Function Capacity (Steps/Day) in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry

Patients were asked to wear an accelerometer during the course of the study which provided information on their physical activity at home, with daily measurements used to investigate the development of physical function capacity. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame: From inclusion into the study to end of the study (up to 18 months)

Population: Participants diagnosed with IPF and non-IPF ILD. Only participants for whom data were collected are included in the analysis.

Arm	Measure	Value (MEAN)	Dispersion
IPF Participants	Decline in Physical Function Capacity (Steps/Day) in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry	-1237.2 Steps per Day	Standard Deviation 14146.07
Non-IPF ILD Participants	Decline in Physical Function Capacity (Steps/Day) in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry	-13407.3 Steps per Day	Standard Deviation 72612.82

Secondary

Fatigue Assessment Scale (FAS) Score During the Peri-Diagnostic Period

The FAS is a fatigue questionnaire consisting of 10 items; five questions reflect physical fatigue and five questions analyze mental fatigue. A five-point scale (one for never to five for always) is used for participant responses. The scale score is calculated by summing all items. Therefore, the FAS scores can range from 10 to 50. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame: From inclusion into the study to end of the study (up to 18 months)

Arm	Measure	Group	Value (MEAN)	Dispersion
IPF Participants	Fatigue Assessment Scale (FAS) Score During the Peri-Diagnostic Period	Baseline	21.8 Scores on a Scale	Standard Deviation 6.44
IPF Participants	Fatigue Assessment Scale (FAS) Score During the Peri-Diagnostic Period	End of study	22.0 Scores on a Scale	Standard Deviation 6.17
IPF Participants	Fatigue Assessment Scale (FAS) Score During the Peri-Diagnostic Period	Initial diagnosis	21.7 Scores on a Scale	Standard Deviation 6.66
Non-IPF ILD Participants	Fatigue Assessment Scale (FAS) Score During the Peri-Diagnostic Period	Baseline	21.8 Scores on a Scale	Standard Deviation 6.89
Non-IPF ILD Participants	Fatigue Assessment Scale (FAS) Score During the Peri-Diagnostic Period	End of study	22.0 Scores on a Scale	Standard Deviation 7.59
Non-IPF ILD Participants	Fatigue Assessment Scale (FAS) Score During the Peri-Diagnostic Period	Initial diagnosis	22.6 Scores on a Scale	Standard Deviation 7.33
Non-ILD Participants	Fatigue Assessment Scale (FAS) Score During the Peri-Diagnostic Period	Baseline	21.1 Scores on a Scale	Standard Deviation 7.22
Non-ILD Participants	Fatigue Assessment Scale (FAS) Score During the Peri-Diagnostic Period	Initial diagnosis	24.7 Scores on a Scale	Standard Deviation 9.11
Non-ILD Participants	Fatigue Assessment Scale (FAS) Score During the Peri-Diagnostic Period	End of study	26.1 Scores on a Scale	Standard Deviation 9.33
Participants Without Diagnosis	Fatigue Assessment Scale (FAS) Score During the Peri-Diagnostic Period	Baseline	20.9 Scores on a Scale	Standard Deviation 6.99
Participants Without Diagnosis	Fatigue Assessment Scale (FAS) Score During the Peri-Diagnostic Period	End of study	20.6 Scores on a Scale	Standard Deviation 6.31
Participants Without Diagnosis	Fatigue Assessment Scale (FAS) Score During the Peri-Diagnostic Period	Initial diagnosis	18.0 Scores on a Scale	Standard Deviation 2.83

Secondary

Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period

The mMRC dyspnea scale was used to grade the effects of breathlessness on daily activities over time. The following grading categories are used for this scale: Grade 0 - I only get breathless with strenuous exercise; Grade 1 - I get short of breath when hurrying on the level or walking up a slight hill; Grade 2 - I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking on my own pace; Grade 3 - I stop for breath after walking about 100 yards or after a few minutes on level ground; Grade 4 - I am too breathless to leave the house. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame: From inclusion into the study to end of the study (up to 18 months)

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 0	22 Participants
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 3	5 Participants
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Post-diagnosis	Grade 0	2 Participants
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 4	0 Participants
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 1	31 Participants
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 2	10 Participants
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 3	5 Participants
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 2	7 Participants
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 2	10 Participants
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Post-diagnosis	Grade 4	0 Participants
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Post-diagnosis	Grade 3	0 Participants
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 4	0 Participants
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 1	30 Participants
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Post-diagnosis	Grade 2	0 Participants
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 0	12 Participants
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 1	8 Participants
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 4	0 Participants
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 0	20 Participants
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Post-diagnosis	Grade 1	4 Participants
IPF Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 3	3 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 0	17 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 2	16 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 3	2 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 3	3 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 4	0 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 4	0 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 1	8 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 1	25 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 1	25 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 2	16 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 3	3 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 2	9 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 4	0 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Post-diagnosis	Grade 0	1 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Post-diagnosis	Grade 1	2 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Post-diagnosis	Grade 2	0 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Post-diagnosis	Grade 3	0 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Post-diagnosis	Grade 4	0 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 0	17 Participants
Non-IPF ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 0	10 Participants
Non-ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 0	3 Participants
Non-ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 3	2 Participants
Non-ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 4	0 Participants
Non-ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 0	3 Participants
Non-ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 4	0 Participants
Non-ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 2	3 Participants
Non-ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 0	2 Participants
Non-ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 1	0 Participants
Non-ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 2	3 Participants
Non-ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 3	2 Participants
Non-ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 3	1 Participants
Non-ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 1	1 Participants
Non-ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 1	1 Participants
Non-ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 4	0 Participants
Non-ILD Participants	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 2	3 Participants
Participants Without Diagnosis	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 4	0 Participants
Participants Without Diagnosis	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 0	6 Participants
Participants Without Diagnosis	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 1	11 Participants
Participants Without Diagnosis	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 2	2 Participants
Participants Without Diagnosis	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 3	1 Participants
Participants Without Diagnosis	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Pre-diagnosis	Grade 4	0 Participants
Participants Without Diagnosis	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 0	2 Participants
Participants Without Diagnosis	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 1	0 Participants
Participants Without Diagnosis	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 2	1 Participants
Participants Without Diagnosis	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 3	0 Participants
Participants Without Diagnosis	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	Initial diagnosis	Grade 4	0 Participants
Participants Without Diagnosis	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 0	13 Participants
Participants Without Diagnosis	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 1	15 Participants
Participants Without Diagnosis	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 2	3 Participants
Participants Without Diagnosis	Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period	End of Study	Grade 3	1 Participants

Secondary

Pearson's Correlation Coefficient of FVC (mL) Between Home and Site Spirometry in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period

The correlation of FVC (mL) between home and site spirometry was analyzed by taking into account the individually estimated linear regression models of each participant for home-based FVC measurements and site FVC measurements. This analysis was performed for participants diagnosed with IPF or non-IPF ILD in the peri-diagnosis period. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame: From inclusion into the study to end of the study (up to 18 months)

Population: Only IPF and non-IPF ILD participants with non-zero declines are included in the analysis.

Arm	Measure	Value (NUMBER)
IPF Participants	Pearson's Correlation Coefficient of FVC (mL) Between Home and Site Spirometry in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period	-0.06 Pearson's Correlation Coefficients
Non-IPF ILD Participants	Pearson's Correlation Coefficient of FVC (mL) Between Home and Site Spirometry in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period	0.35 Pearson's Correlation Coefficients

Secondary

Pearson's Correlation Coefficient of Physical Functional Capacity Assessed at Home in Terms of the Decline in the Number of Footsteps and on Site in Terms of the Decline in Distance of the 6MWT

The measure represents the correlation of distance walked (meter) assessed by physical function capacity at home and the 6MWT at the site in the peri-diagnosis period. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame: From inclusion into the study to end of the study (up to 18 months)

Population: Only IPF and non-IPF ILD participants with non-zero declines are included in the analysis.

Arm	Measure	Value (NUMBER)
IPF Participants	Pearson's Correlation Coefficient of Physical Functional Capacity Assessed at Home in Terms of the Decline in the Number of Footsteps and on Site in Terms of the Decline in Distance of the 6MWT	-0.04 Pearson's Correlation Coefficients
Non-IPF ILD Participants	Pearson's Correlation Coefficient of Physical Functional Capacity Assessed at Home in Terms of the Decline in the Number of Footsteps and on Site in Terms of the Decline in Distance of the 6MWT	0.06 Pearson's Correlation Coefficients

Secondary

Percentage of Participants Requiring Respiratory-Related Hospitalizations

The number of participants requiring the hospitalization were counted during pre- and post-diagnosis period.

Time frame: From inclusion into the study to end of the study (up to 18 months)

Population: All enrolled participants.

Arm	Measure	Group	Value (NUMBER)
IPF Participants	Percentage of Participants Requiring Respiratory-Related Hospitalizations	With at least one event during pre-diagnosis period	5.9 Percentage of Participants
IPF Participants	Percentage of Participants Requiring Respiratory-Related Hospitalizations	With at least one event during post-diagnosis period	0 Percentage of Participants
Non-IPF ILD Participants	Percentage of Participants Requiring Respiratory-Related Hospitalizations	With at least one event during post-diagnosis period	0 Percentage of Participants
Non-IPF ILD Participants	Percentage of Participants Requiring Respiratory-Related Hospitalizations	With at least one event during pre-diagnosis period	4.8 Percentage of Participants
Non-ILD Participants	Percentage of Participants Requiring Respiratory-Related Hospitalizations	With at least one event during pre-diagnosis period	22.2 Percentage of Participants
Non-ILD Participants	Percentage of Participants Requiring Respiratory-Related Hospitalizations	With at least one event during post-diagnosis period	0 Percentage of Participants
Participants Without Diagnosis	Percentage of Participants Requiring Respiratory-Related Hospitalizations	With at least one event during pre-diagnosis period	2.6 Percentage of Participants
Participants Without Diagnosis	Percentage of Participants Requiring Respiratory-Related Hospitalizations	With at least one event during post-diagnosis period	0 Percentage of Participants

Secondary

Percentage of Participants Who Died Due to Any Cause

The number of participants, who died due to any cause, were counted during pre- and post-diagnosis period.

Time frame: From inclusion into the study to end of the study (up to 18 months)

Population: All enrolled participants.

Arm	Measure	Value (NUMBER)
IPF Participants	Percentage of Participants Who Died Due to Any Cause	0 Percentage of Participants
Non-IPF ILD Participants	Percentage of Participants Who Died Due to Any Cause	0 Percentage of Participants
Non-ILD Participants	Percentage of Participants Who Died Due to Any Cause	0 Percentage of Participants
Participants Without Diagnosis	Percentage of Participants Who Died Due to Any Cause	0 Percentage of Participants

Secondary

Percentage of Participants Who Died Due to Respiratory-Related Diseases

The number of participants, who died due to respiratory-related diseases, were counted during pre- and post-diagnosis period.

Time frame: From inclusion into the study to end of the study (up to 18 months)

Population: All enrolled participants.

Arm	Measure	Value (NUMBER)
IPF Participants	Percentage of Participants Who Died Due to Respiratory-Related Diseases	0 Percentage of Participants
Non-IPF ILD Participants	Percentage of Participants Who Died Due to Respiratory-Related Diseases	0 Percentage of Participants
Non-ILD Participants	Percentage of Participants Who Died Due to Respiratory-Related Diseases	0 Percentage of Participants
Participants Without Diagnosis	Percentage of Participants Who Died Due to Respiratory-Related Diseases	0 Percentage of Participants

Secondary

Percentage of Participants With Events Related to the Study Assessments

The number of participants with events related to the study assessments were counted during pre- and post-diagnosis period. Investigator-reported acute exacerbations, deaths, and events related to study assessments were only collected in the clinical database. As the study had no protocol mandated IMP or treatment requirements, any untoward occurrences such as AEs and SAEs were not collected.

Time frame: From inclusion into the study to end of the study (up to 18 months)

Population: All enrolled participants.

Arm	Measure	Value (NUMBER)
IPF Participants	Percentage of Participants With Events Related to the Study Assessments	0 Percentage of Participants
Non-IPF ILD Participants	Percentage of Participants With Events Related to the Study Assessments	3.2 Percentage of Participants
Non-ILD Participants	Percentage of Participants With Events Related to the Study Assessments	0 Percentage of Participants
Participants Without Diagnosis	Percentage of Participants With Events Related to the Study Assessments	5.1 Percentage of Participants

Secondary

Percentage of Participants With Investigator-Reported Acute Exacerbations

Acute exacerbation was defined as per Collard et al. 2016. Investigator-reported acute exacerbations, deaths, and events related to study assessments were only collected in the clinical database. As the study had no protocol mandated IMP or treatment requirements, any untoward occurrences such as AEs and SAEs were not collected.

Time frame: From inclusion into the study to end of the study (up to 18 months)

Population: All enrolled participants. Data of post-diagnosis period for non-ILD participants and participants without diagnosis were not collected.

Arm	Measure	Group	Value (NUMBER)
IPF Participants	Percentage of Participants With Investigator-Reported Acute Exacerbations	With at least one triggered acute exacerbation pre-diagnosis period	4.4 Percentage of Participants
IPF Participants	Percentage of Participants With Investigator-Reported Acute Exacerbations	With at least one idiopathic acute exacerbation during post-diagnosis period	0 Percentage of Participants
IPF Participants	Percentage of Participants With Investigator-Reported Acute Exacerbations	With at least one idiopathic acute exacerbation pre-diagnosis period	0 Percentage of Participants
IPF Participants	Percentage of Participants With Investigator-Reported Acute Exacerbations	With at least one triggered acute exacerbation during post-diagnosis period	0 Percentage of Participants
IPF Participants	Percentage of Participants With Investigator-Reported Acute Exacerbations	With at least one acute exacerbation during post-diagnosis period	0 Percentage of Participants
IPF Participants	Percentage of Participants With Investigator-Reported Acute Exacerbations	With at least one acute exacerbation pre-diagnosis period	1.5 Percentage of Participants
Non-IPF ILD Participants	Percentage of Participants With Investigator-Reported Acute Exacerbations	With at least one idiopathic acute exacerbation during post-diagnosis period	0 Percentage of Participants
Non-IPF ILD Participants	Percentage of Participants With Investigator-Reported Acute Exacerbations	With at least one acute exacerbation pre-diagnosis period	0 Percentage of Participants
Non-IPF ILD Participants	Percentage of Participants With Investigator-Reported Acute Exacerbations	With at least one acute exacerbation during post-diagnosis period	0 Percentage of Participants
Non-IPF ILD Participants	Percentage of Participants With Investigator-Reported Acute Exacerbations	With at least one triggered acute exacerbation pre-diagnosis period	0 Percentage of Participants
Non-IPF ILD Participants	Percentage of Participants With Investigator-Reported Acute Exacerbations	With at least one triggered acute exacerbation during post-diagnosis period	0 Percentage of Participants
Non-IPF ILD Participants	Percentage of Participants With Investigator-Reported Acute Exacerbations	With at least one idiopathic acute exacerbation pre-diagnosis period	1.6 Percentage of Participants
Non-ILD Participants	Percentage of Participants With Investigator-Reported Acute Exacerbations	With at least one triggered acute exacerbation pre-diagnosis period	0 Percentage of Participants
Non-ILD Participants	Percentage of Participants With Investigator-Reported Acute Exacerbations	With at least one acute exacerbation pre-diagnosis period	0 Percentage of Participants
Non-ILD Participants	Percentage of Participants With Investigator-Reported Acute Exacerbations	With at least one idiopathic acute exacerbation pre-diagnosis period	0 Percentage of Participants
Participants Without Diagnosis	Percentage of Participants With Investigator-Reported Acute Exacerbations	With at least one idiopathic acute exacerbation pre-diagnosis period	0 Percentage of Participants
Participants Without Diagnosis	Percentage of Participants With Investigator-Reported Acute Exacerbations	With at least one triggered acute exacerbation pre-diagnosis period	0 Percentage of Participants
Participants Without Diagnosis	Percentage of Participants With Investigator-Reported Acute Exacerbations	With at least one acute exacerbation pre-diagnosis period	0 Percentage of Participants

Secondary

Percentage of Participants With Non-Elective Hospitalizations

The number of participants requiring the hospitalization were counted during pre- and post-diagnosis period. Investigator-reported acute exacerbations, deaths, and events related to study assessments were only collected in the clinical database. As the study had no protocol mandated IMP or treatment requirements, any untoward occurrences such as AEs and SAEs were not collected.

Time frame: From inclusion into the study to end of the study (up to 18 months)

Population: All enrolled participants.

Arm	Measure	Group	Value (NUMBER)
IPF Participants	Percentage of Participants With Non-Elective Hospitalizations	With at least one event during pre-diagnosis period	8.8 Percentage of Participants
IPF Participants	Percentage of Participants With Non-Elective Hospitalizations	With at least one event during post-diagnosis period	2.9 Percentage of Participants
Non-IPF ILD Participants	Percentage of Participants With Non-Elective Hospitalizations	With at least one event during post-diagnosis period	0 Percentage of Participants
Non-IPF ILD Participants	Percentage of Participants With Non-Elective Hospitalizations	With at least one event during pre-diagnosis period	4.8 Percentage of Participants
Non-ILD Participants	Percentage of Participants With Non-Elective Hospitalizations	With at least one event during pre-diagnosis period	22.2 Percentage of Participants
Non-ILD Participants	Percentage of Participants With Non-Elective Hospitalizations	With at least one event during post-diagnosis period	0 Percentage of Participants
Participants Without Diagnosis	Percentage of Participants With Non-Elective Hospitalizations	With at least one event during pre-diagnosis period	7.7 Percentage of Participants
Participants Without Diagnosis	Percentage of Participants With Non-Elective Hospitalizations	With at least one event during post-diagnosis period	0 Percentage of Participants

Secondary

The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period

The EQ-5D-5L questionnaire is a self-reported health status questionnaire that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each item is rated by the participant on a five-point scale indicating the followings: Level 1 - no problem; Level 2 - slight problems; Level 3 - moderate problems; Level 4 - severe problems; Level 5 - extreme problems. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame: From inclusion into the study to end of the study (up to 18 months)

Population: All enrolled participants. Data of post-diagnosis period for non-ILD participants and participants without diagnosis were not collected as participants already discontinued from the study.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 2	21 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 1	15 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 4	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 1	30 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Missing	3 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 2	11 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 3	17 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 5	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 4	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 3	3 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Missing	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 3	10 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 2	22 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 4	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 3	13 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 1	32 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Missing	3 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 5	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 2	20 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 5	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 4	4 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Missing	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 4	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 3	9 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 2	20 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 1	14 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 2	19 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 1	31 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Missing	3 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 2	11 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 1	30 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 5	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 4	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 3	3 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Missing	2 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 3	6 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 2	3 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 4	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 5	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 1	55 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Missing	3 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 5	2 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Missing	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 5	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 4	3 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Missing	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 5	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 3	12 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 2	19 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 1	31 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 4	3 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Missing	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 5	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 3	11 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 2	16 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 1	38 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 4	5 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 1	32 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Missing	2 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 2	22 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 3	16 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 5	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 4	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 3	5 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 5	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 3	5 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 2	3 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 4	2 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 3	14 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 1	54 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Missing	2 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 5	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 2	16 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 5	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 4	4 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Missing	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 4	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 3	11 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 2	15 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 1	16 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 3	6 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 1	33 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Anxiety/Depression	Missing	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 2	4 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 1	33 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Anxiety/Depression	Level 5	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Anxiety/Depression	Level 4	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 3	9 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Missing	2 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Anxiety/Depression	Level 3	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Anxiety/Depression	Level 2	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 4	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 5	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Anxiety/Depression	Level 1	3 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Pain/Discomfort	Missing	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 5	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 2	7 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Pain/Discomfort	Level 5	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Pain/Discomfort	Level 4	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Missing	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 5	2 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Pain/Discomfort	Level 3	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Pain/Discomfort	Level 2	4 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 1	25 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 4	2 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Pain/Discomfort	Level 1	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Usual activities	Missing	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 2	3 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Missing	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Usual activities	Level 5	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Usual activities	Level 4	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 3	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 1	32 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Usual activities	Level 3	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Usual activities	Level 2	2 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 4	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 3	10 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Usual activities	Level 1	2 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Self-care	Missing	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 5	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 2	21 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Self-care	Level 5	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Self-care	Level 4	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Missing	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 1	29 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Self-care	Level 3	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Self-care	Level 2	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 1	15 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 4	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Self-care	Level 1	4 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Mobility	Missing	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 2	10 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 1	28 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Mobility	Level 5	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Mobility	Level 4	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 3	4 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Missing	2 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Mobility	Level 3	2 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Mobility	Level 2	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 4	1 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 2	22 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Mobility	Level 1	2 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Missing	3 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 5	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 1	55 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 5	2 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 4	2 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Missing	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 5	0 Participants
IPF Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 3	10 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Missing	2 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Missing	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 1	29 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 2	16 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 3	15 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 4	2 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Missing	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 1	25 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 2	22 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 3	14 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 4	1 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Missing	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 1	24 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 2	20 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 3	15 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 4	2 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 5	1 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Missing	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 1	11 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 2	9 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 3	5 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 4	3 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Missing	1 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 1	25 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 2	2 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 3	1 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 4	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Missing	1 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 1	15 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 2	6 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 3	7 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 4	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Missing	1 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 1	15 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 2	7 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 3	5 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 4	1 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Missing	1 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 1	12 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 2	10 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 3	6 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 4	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Missing	1 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 1	26 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 2	17 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 3	9 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 4	6 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Missing	4 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 1	44 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 2	10 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 3	4 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 4	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Missing	4 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 1	27 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 2	14 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 3	14 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 4	3 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Missing	4 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 1	34 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 2	14 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 3	6 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 4	4 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Missing	4 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 1	25 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 2	17 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 3	13 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 4	3 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Missing	4 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Mobility	Level 1	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Mobility	Level 2	2 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Mobility	Level 3	1 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Mobility	Level 4	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Mobility	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Mobility	Missing	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Self-care	Level 1	2 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Self-care	Level 2	1 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Self-care	Level 3	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Self-care	Level 4	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Self-care	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Self-care	Missing	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Usual activities	Level 1	2 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Usual activities	Level 2	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Usual activities	Level 3	1 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Usual activities	Level 4	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Usual activities	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Usual activities	Missing	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Pain/Discomfort	Level 1	2 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Pain/Discomfort	Level 2	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Pain/Discomfort	Level 3	1 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Pain/Discomfort	Level 4	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Pain/Discomfort	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Pain/Discomfort	Missing	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Anxiety/Depression	Level 1	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Anxiety/Depression	Level 2	2 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Anxiety/Depression	Level 3	1 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Anxiety/Depression	Level 4	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Anxiety/Depression	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Post-diagnosis Anxiety/Depression	Missing	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 1	28 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 2	15 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 3	14 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 4	3 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Missing	2 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 1	46 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 2	12 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 3	2 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 4	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Missing	2 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 1	25 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 2	18 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 3	15 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 4	2 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Missing	2 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 1	34 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 2	16 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 3	8 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 4	2 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 1	25 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 2	19 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 3	15 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 4	1 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Missing	2 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 1	25 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 2	15 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 3	21 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 4	1 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 5	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Missing	0 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 1	52 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 2	6 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 3	4 Participants
Non-IPF ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 4	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 4	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 2	1 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 3	1 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 2	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 4	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 5	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 5	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 5	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 4	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 3	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 1	4 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 2	3 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 1	3 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 1	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 5	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 1	4 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 5	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 1	6 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 2	1 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 4	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 3	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 3	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 2	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 1	5 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 4	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 5	1 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 5	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 4	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 5	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 4	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 3	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 2	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 2	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 4	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 1	1 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 1	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 1	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 2	3 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 3	3 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 4	1 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 5	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 5	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 2	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 4	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 1	6 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 3	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 2	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 3	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 3	1 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 3	5 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 4	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 2	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 5	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 1	5 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 3	1 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 1	4 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 4	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 2	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 3	4 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 2	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 1	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 4	1 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 2	3 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 3	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 5	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 4	1 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 5	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 5	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 5	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 4	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 1	6 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 2	1 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 3	1 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 5	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 3	1 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 4	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 2	4 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 5	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 4	1 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 1	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 1	6 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 1	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 2	1 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 3	1 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 4	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 5	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 5	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 2	1 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 4	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 1	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 3	3 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 2	1 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 3	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 3	3 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 3	4 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 4	2 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 2	4 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 5	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 1	1 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Missing	0 Participants
Non-ILD Participants	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 1	4 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 3	4 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 5	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 2	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 5	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 4	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 1	19 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 3	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 5	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 2	10 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 1	10 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 4	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Missing	9 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Missing	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Missing	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 5	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 4	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 1	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Missing	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Missing	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 1	14 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 5	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 3	4 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 1	20 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Missing	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 3	4 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 2	6 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 5	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 2	5 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Missing	9 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Level 1	9 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 3	6 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 4	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 1	2 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Missing	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 3	4 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 5	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 1	13 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 5	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Missing	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Missing	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Usual activities	Missing	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 4	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 1	2 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Missing	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 2	10 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 3	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 2	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 2	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 1	34 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 2	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 2	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 5	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 3	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Self-care	Level 1	20 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 5	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 4	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Missing	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Missing	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 1	14 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 3	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 4	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 5	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 5	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 5	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 3	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 4	2 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 4	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 5	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Level 5	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 3	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 4	4 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 3	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 3	4 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 2	4 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Level 5	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 4	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Anxiety/Depression	Missing	9 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Mobility	Level 1	13 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 1	12 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 4	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 2	4 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Mobility	Missing	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 1	16 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Missing	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 3	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Level 5	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 2	2 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 1	20 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 1	24 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 1	2 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 3	4 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 5	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Usual activities	Level 3	4 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 3	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 4	2 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 4	3 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 2	3 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 2	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Level 5	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 4	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Level 5	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Pain/Discomfort	Level 4	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Mobility	Missing	9 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Pain/Discomfort	Level 2	10 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Mobility	Level 2	9 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 3	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 1	22 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 3	7 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Pre-diagnosis Anxiety/Depression	Level 2	8 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Anxiety/Depression	Level 1	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 2	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Usual activities	Missing	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Self-care	Level 4	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Self-care	Level 4	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 3	1 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Baseline Anxiety/Depression	Level 2	12 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	Initial diagnosis Pain/Discomfort	Level 4	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Usual activities	Missing	9 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Self-care	Level 4	0 Participants
Participants Without Diagnosis	The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period	End of Study Pain/Discomfort	Level 2	3 Participants

Secondary

The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period

The EQ-5D-5L questionnaire is a self-reported health status questionnaire that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. A unique health state is defined for each participant by combining the levels from each of the 5 dimensions. Each state is referred to in terms of a 5 digit code, e.g. state 11111 indicates no problems on any of the 5 dimensions, while state 12345 indicates no problems with mobility, slight problems with washing or dressing, moderate problems with usual activities, severe pain or discomfort and extreme anxiety or depression. From these 5 answers an index value is derived between 0 and 1, with a higher value corresponding with a better Quality of Life.

Time frame: From inclusion into the study to end of the study (up to 18 months)

Arm	Measure	Group	Value (MEAN)	Dispersion
IPF Participants	The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period	Index utility score End of Study	0.81 Scores on a scale	Standard Deviation 0.164
IPF Participants	The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period	Index utility score Baseline	0.83 Scores on a scale	Standard Deviation 0.14
IPF Participants	The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period	Index utility score Initial diagnosis	0.81 Scores on a scale	Standard Deviation 0.162
IPF Participants	The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period	Index utility score Post-diagnosis	0.81 Scores on a scale	Standard Deviation 0.149
IPF Participants	The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period	Index utility score Pre-diagnosis	0.82 Scores on a scale	Standard Deviation 0.154
Non-IPF ILD Participants	The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period	Index utility score Initial diagnosis	0.78 Scores on a scale	Standard Deviation 0.197
Non-IPF ILD Participants	The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period	Index utility score Baseline	0.79 Scores on a scale	Standard Deviation 0.143
Non-IPF ILD Participants	The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period	Index utility score Pre-diagnosis	0.80 Scores on a scale	Standard Deviation 0.152
Non-IPF ILD Participants	The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period	Index utility score Post-diagnosis	0.75 Scores on a scale	Standard Deviation 0.123
Non-IPF ILD Participants	The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period	Index utility score End of Study	0.80 Scores on a scale	Standard Deviation 0.164
Non-ILD Participants	The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period	Index utility score Pre-diagnosis	0.68 Scores on a scale	Standard Deviation 0.237
Non-ILD Participants	The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period	Index utility score End of Study	0.62 Scores on a scale	Standard Deviation 0.312
Non-ILD Participants	The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period	Index utility score Baseline	0.67 Scores on a scale	Standard Deviation 0.25
Non-ILD Participants	The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period	Index utility score Initial diagnosis	0.63 Scores on a scale	Standard Deviation 0.331
Participants Without Diagnosis	The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period	Index utility score Pre-diagnosis	0.83 Scores on a scale	Standard Deviation 0.182
Participants Without Diagnosis	The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period	Index utility score Initial diagnosis	0.92 Scores on a scale	Standard Deviation 0.013
Participants Without Diagnosis	The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period	Index utility score Baseline	0.80 Scores on a scale	Standard Deviation 0.187
Participants Without Diagnosis	The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period	Index utility score End of Study	0.81 Scores on a scale	Standard Deviation 0.197

Secondary

The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period

The EQ-VAS questionnaire is a self-reported questionnaire that measures health state. The VAS is a 100 mm scale from worst (0 mm) to best (100 mm) health the participant can imagine. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame: From inclusion into the study to end of the study (up to 18 months)

Arm	Measure	Group	Value (MEAN)	Dispersion
IPF Participants	The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period	Health State Index End of Study	69.5 Scores on a scale	Standard Deviation 16.46
IPF Participants	The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period	Health State Index Baseline	71.7 Scores on a scale	Standard Deviation 15.96
IPF Participants	The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period	Health State Index Initial diagnosis	69.5 Scores on a scale	Standard Deviation 16.23
IPF Participants	The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period	Health State Index Post-diagnosis	69.0 Scores on a scale	Standard Deviation 25.1
IPF Participants	The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period	Health State Index Pre-diagnosis	69.8 Scores on a scale	Standard Deviation 15.5
Non-IPF ILD Participants	The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period	Health State Index Initial diagnosis	68.3 Scores on a scale	Standard Deviation 18.03
Non-IPF ILD Participants	The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period	Health State Index Baseline	67.4 Scores on a scale	Standard Deviation 20.11
Non-IPF ILD Participants	The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period	Health State Index Pre-diagnosis	71.5 Scores on a scale	Standard Deviation 15.89
Non-IPF ILD Participants	The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period	Health State Index Post-diagnosis	76.7 Scores on a scale	Standard Deviation 12.58
Non-IPF ILD Participants	The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period	Health State Index End of Study	69.8 Scores on a scale	Standard Deviation 17.21
Non-ILD Participants	The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period	Health State Index Pre-diagnosis	65.7 Scores on a scale	Standard Deviation 19.88
Non-ILD Participants	The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period	Health State Index End of Study	67.0 Scores on a scale	Standard Deviation 21.21
Non-ILD Participants	The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period	Health State Index Baseline	68.9 Scores on a scale	Standard Deviation 17.99
Non-ILD Participants	The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period	Health State Index Initial diagnosis	70.4 Scores on a scale	Standard Deviation 19.92
Participants Without Diagnosis	The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period	Health State Index Pre-diagnosis	73.5 Scores on a scale	Standard Deviation 16.06
Participants Without Diagnosis	The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period	Health State Index Initial diagnosis	72.5 Scores on a scale	Standard Deviation 10.61
Participants Without Diagnosis	The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period	Health State Index Baseline	76.2 Scores on a scale	Standard Deviation 17.09
Participants Without Diagnosis	The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period	Health State Index End of Study	74.2 Scores on a scale	Standard Deviation 16.85

Secondary

Time-Adjusted Semi-Annual FVC Decline in Participants With Non-IPF ILD During the Peri-Diagnostic Period, Measured in mL by Daily Home Spirometry

Population: Participants diagnosed with non-IPF ILD. Only participants for whom data were collected are included in the analysis.

Arm	Measure	Value (MEAN)	Dispersion
IPF Participants	Time-Adjusted Semi-Annual FVC Decline in Participants With Non-IPF ILD During the Peri-Diagnostic Period, Measured in mL by Daily Home Spirometry	57.5 mL	Standard Deviation 1277.03

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026

A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period

Conditions

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Time-Adjusted Semi-Annual Forced Vital Capacity (FVC) Decline in Participants With IPF During the Peri-Diagnostic Period, Measured in Milliliters (mL) by Daily Home Spirometry

Calorie Expenditure in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry

Change From Baseline in Distance Walked (Meters) on the 6MWT in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Assessed at Site

Change From Baseline in the FVC Decline in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured in mL by Site Spirometry

Change From Baseline in the Percent Predicted FVC in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Site Spirometry

Change in the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score by Visit During the Peri-Diagnostic Period

Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period

Decline in Physical Function Capacity (Steps/Day) in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry

Fatigue Assessment Scale (FAS) Score During the Peri-Diagnostic Period

Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period

Pearson's Correlation Coefficient of FVC (mL) Between Home and Site Spirometry in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period

Pearson's Correlation Coefficient of Physical Functional Capacity Assessed at Home in Terms of the Decline in the Number of Footsteps and on Site in Terms of the Decline in Distance of the 6MWT

Percentage of Participants Requiring Respiratory-Related Hospitalizations

Percentage of Participants Who Died Due to Any Cause

Percentage of Participants Who Died Due to Respiratory-Related Diseases

Percentage of Participants With Events Related to the Study Assessments

Percentage of Participants With Investigator-Reported Acute Exacerbations

Percentage of Participants With Non-Elective Hospitalizations

The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period

The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period

The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period

Time-Adjusted Semi-Annual FVC Decline in Participants With Non-IPF ILD During the Peri-Diagnostic Period, Measured in mL by Daily Home Spirometry